234 related articles for article (PubMed ID: 18443563)
1. Melatonin: adjuvant therapy of malignant tumors.
Dziegiel P; Podhorska-Okolow M; Zabel M
Med Sci Monit; 2008 May; 14(5):RA64-70. PubMed ID: 18443563
[TBL] [Abstract][Full Text] [Related]
2. Melatonin in clinical oncology.
Bartsch C; Bartsch H; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():30-8. PubMed ID: 12019349
[TBL] [Abstract][Full Text] [Related]
3. [Significance of melatonin in malignant diseases].
Bartsch C; Bartsch H
Wien Klin Wochenschr; 1997 Oct; 109(18):722-9. PubMed ID: 9441515
[TBL] [Abstract][Full Text] [Related]
4. Oncostatic action of melatonin: facts and question marks.
Pawlikowski M; Winczyk K; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():24-9. PubMed ID: 12019348
[TBL] [Abstract][Full Text] [Related]
5. Melatonin and mammary pathological growth.
Cos S; Sánchez-Barceló EJ
Front Neuroendocrinol; 2000 Apr; 21(2):133-70. PubMed ID: 10764528
[TBL] [Abstract][Full Text] [Related]
6. Melatonin in cancer management: progress and promise.
Jung B; Ahmad N
Cancer Res; 2006 Oct; 66(20):9789-93. PubMed ID: 17047036
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.
Witt-Enderby PA; Radio NM; Doctor JS; Davis VL
J Pineal Res; 2006 Nov; 41(4):297-305. PubMed ID: 17014686
[TBL] [Abstract][Full Text] [Related]
8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
9. New perspectives in melatonin uses.
Carpentieri A; Díaz de Barboza G; Areco V; Peralta López M; Tolosa de Talamoni N
Pharmacol Res; 2012 Apr; 65(4):437-44. PubMed ID: 22311380
[TBL] [Abstract][Full Text] [Related]
10. Role of melatonin in cancer treatment.
Cutando A; López-Valverde A; Arias-Santiago S; DE Vicente J; DE Diego RG
Anticancer Res; 2012 Jul; 32(7):2747-53. PubMed ID: 22753734
[TBL] [Abstract][Full Text] [Related]
11. [Hormones and cytostatic drugs in cancer chemotherapy].
Matthias M
Z Gesamte Inn Med; 1978 Jul; 33(14):459-65. PubMed ID: 211742
[TBL] [Abstract][Full Text] [Related]
12. [Anticarcinogenic role of melatonin--potential mechanisms].
Bukowska A
Med Pr; 2011; 62(4):425-34. PubMed ID: 21995112
[TBL] [Abstract][Full Text] [Related]
13. Melatonin: new places in therapy.
Maharaj DS; Glass BD; Daya S
Biosci Rep; 2007 Dec; 27(6):299-320. PubMed ID: 17828452
[TBL] [Abstract][Full Text] [Related]
14. [Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents].
Jeney A; Kralovánszky J
Orv Hetil; 1999 Jun; 140(24):1339-45. PubMed ID: 10439634
[TBL] [Abstract][Full Text] [Related]
15. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
16. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line.
Watanabe M; Kobayashi Y; Takahashi N; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2008 Aug; 34(4):567-73. PubMed ID: 18937711
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic actions of melatonin in cancer: possible mechanisms.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
[TBL] [Abstract][Full Text] [Related]
18. [Cytostatic drugs--mechanism of action and guidelines for clinical use].
Sauer H
Fortschr Med; 1989 Oct; 107(29):604-11. PubMed ID: 2680840
[TBL] [Abstract][Full Text] [Related]
19. Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitro.
Kulcsár G
Cancer Biother Radiopharm; 2009 Feb; 24(1):67-80. PubMed ID: 19243249
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN; Perez SA; Papamichail M
Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
